



**Guard Medical reports follow-on \$5 million cash infusion following FDA 510k clearance for its novel NPseal™, the first all-in-one NPWT surgical dressing**

New York, June 29, 2020 – Privately-held [Guard Medical Inc.](http://www.guard-medical.com) today announces a substantial cash infusion of \$5 million following the achievement of the important milestone of FDA 510k clearance for its next generation Negative Pressure Wound Therapy (NPWT) dressing **NPseal™** for the treatment of closed surgical incisions. Guard Medical's simple, innovative and cost-effective NPWT **NPseal™** is a wearable dressing with an integrated pump that establishes and maintains negative pressure with just a few pinches.

"Releasing the 2<sup>nd</sup> investment tranche following the FDA clearance for our **NPseal™** will allow us to accelerate market introduction and post-market clinical investigations," stated **Machiel van der Leest**, CEO of Guard Medical. "We will further demonstrate the unique benefits of NPseal's ease-of-use and cost-efficiency. Our goal is to make NPWT accessible to all patients."

NPWT has been shown to reduce Surgical Site Infections (SSI) in a large number of peer reviewed articles, but is in limited use due to its high cost and complexity. While being easy-to-use, **NPseal™** delivers the same NPWT as current more expensive and complex NPWT devices.

- end -

*Guard Medical Inc. ([www.guard-medical.com](http://www.guard-medical.com)), a privately-held company, is developing easy-to-use and cost-effective solutions that enable prophylactic Negative Pressure Wound Therapy (NPWT) wound care of closed surgical incisions. Guard Medical's simple NPWT technology originated with NewYork-Presbyterian and Weill Cornell Medicine in response to physicians' identification of unmet needs related to Surgical Site Infections (SSI). Current investors include Bpifrance and Matignon Investissement et Gestion.*

*Guard Medical's vision is to develop NPWT solutions for use on a wide range of surgical wound types and sizes with broad applications for infection prevention, scar mitigation and enhanced cosmesis.*

For further information please contact: Dr. Frederick Cornhill  
Chief Scientific Officer, Guard Medical  
E: [j.cornhill@guard-medical.com](mailto:j.cornhill@guard-medical.com)